Oteracil

Summary

Oteracil (CHEMBL181932) is a phase-3 clinical-stage small molecule; indicated across 35 conditions including colorectal adenocarcinoma and gastric adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 35 conditions
• Clinical trials: 11
• Chemistry: 157.08 Da · C4H3N3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL181932
Name	Oteracil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	4604
ChEBI	CHEBI:30863
Molecular formula	C4H3N3O4
Molecular weight	157.08
InChIKey	RYYCJUAHISIHTL-UHFFFAOYSA-N

SMILES: C1(=NC(=O)NC(=O)N1)C(=O)O

IUPAC name: 4,6-dioxo-1H-1,3,5-triazine-2-carboxylic acid

Also known as: Allantoxanic acid, Oteracil, Oteracilo, Oxonic acid, SID29217994, SID174006211, OTERACIL, Oxonic_acid potassium salt

Parent form; salt/anhydrous children: CHEMBL3184847

Patent coverage: 851 distinct patent families (2,009 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,994 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.55	Potency	281.8	nM	CHEMBL_ACT_3644638

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

26 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
colorectal adenocarcinoma	3	MONDO:0005008	EFO:0000365
gastric adenocarcinoma	3	MONDO:0005036	EFO:0000503
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
carcinoma of esophagus	3	MONDO:0019086	EFO:0002916
gastric neoplasm	3	MONDO:0021085	EFO:0003897
colorectal neoplasm	3	MONDO:0005335	EFO:0004142
cholangiocarcinoma	3	MONDO:0019087	EFO:0005221
esophageal squamous cell carcinoma	3	MONDO:0005580	EFO:0005922
head and neck cancer	3	MONDO:0005627	EFO:0006859
adenocarcinoma	3	MONDO:0004970	EFO:0000228
pancreatic neoplasm	3	MONDO:0021040	EFO:0003860
gastric carcinoma	3	MONDO:0004950	EFO:0000178
malignant pancreatic neoplasm	3	MONDO:0009831	EFO:1000359
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
neoplasm	2	MONDO:0005070	EFO:0000616
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
breast neoplasm	2	MONDO:0021100	EFO:0003869
rectal cancer	2	MONDO:0006519	EFO:1000657
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
neuroendocrine carcinoma	2	MONDO:0002120	MONDO:0002120
rectal neoplasm	2	MONDO:0002165	MONDO:0044937
pancreatic ductal adenocarcinoma	2	MONDO:0005184	MONDO:0005184
nasopharyngeal carcinoma	2	MONDO:0015459	MONDO:0015459
liver disorder	1	MONDO:0005154	EFO:0001421
kidney disorder	1	MONDO:0005240	EFO:0003086

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	3
PHASE2/PHASE3	2
PHASE4	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05498766	PHASE4	NOT_YET_RECRUITING	Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
NCT06109779	PHASE3	ACTIVE_NOT_RECRUITING	Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT00503321	PHASE2/PHASE3	TERMINATED	Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
NCT01516944	PHASE2/PHASE3	COMPLETED	Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
NCT02008422	PHASE3	UNKNOWN	Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer
NCT03448549	PHASE3	UNKNOWN	SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients
NCT05934331	PHASE2	RECRUITING	A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
NCT06487702	PHASE2	NOT_YET_RECRUITING	A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT02749526	PHASE2	TERMINATED	Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial
NCT04310774	PHASE1/PHASE2	UNKNOWN	CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer
NCT04571489	PHASE2	UNKNOWN	A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).